Diabetes drug tested to boost heart procedure success
NCT ID NCT04625946
Summary
This study tested whether adding the diabetes medication metformin to a standard heart ablation procedure helps prevent the return of atrial fibrillation (AFib), an irregular heartbeat. It involved 117 overweight adults without diabetes who were scheduled for ablation. Researchers compared those who received metformin for a year after the procedure to those who did not, tracking heart rhythm and symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.